18.43USD+0.30%Mkt Cap: —P/E: 5.871d ago
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead p…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value1.40B $
Revenue (TTM)38.42M $
Gross Profit14.73M $
Net Income (TTM)116.53M $
Revenue/Share0.5460 USD
Last Price18.43 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees175
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS6821431029
Valuation
P/E (Trailing)5.87
P/E (Forward)—
PEG—
EV/EBITDA-19.42
EV/Revenue36.34
P/S—
P/B-24.26
EPS (TTM)3.14
EPS (Forward)—
52W Range
16.9689% of range18.62
52W High18.62 USD
52W Low16.96 USD
Profitability
Gross Margin38.34%
Oper. Margin0.26%
EBITDA Margin-187.17%
Profit Margin324.88%
ROE—
ROA-18.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-68.67M $
CapEx (TTM)—
FCF Margin477.10%
FCF Yield—
Net Debt164.92M $
Net Debt/EBITDA-2.29
Balance Sheet
Debt/Equity—
Current Ratio1.95
Quick Ratio1.61
Book Value/Sh-0.7120 USD
Cash/Share1.823 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.49.01M
Float69.81M
Insiders3.56%
Institutions50.49%
Technical
SMA 503.743 (+392.5%)
SMA 2004.070 (+352.9%)
Beta2.54
S&P 52W Chg20.80%
Avg Vol (30d)4.37K
Avg Vol (10d)1.11K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—